Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima–media thickness: a pilot study

M. -C. Lacasse¹, A. Tang¹,², J. Dubois³,⁴, F. Alvarez⁴,⁵, S. Spahis⁴,⁵,⁶, M. Chagnon⁷, S. Deschênes³,⁴ and E. Levy⁴,⁵

¹Department of Radiology, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada; ²Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec, Canada; ³Department of Radiology, Centre Hospitalier Universitaire Ste-Justine, Montréal, Québec, Canada; ⁴Centre de Recherche du Centre Hospitalier Universitaire Ste-Justine, Montréal, Québec, Canada; ⁵Department of Nutrition, Université de Montréal, Québec, Canada; ⁶Department of Mathematics and Statistics, Pavillon André-Aisenstadt, Université de Montréal, Montréal, Québec, Canada; ⁷Department of Mathematics and Statistics, Pavillon André-Aisenstadt, Université de Montréal, Montréal, Québec, Canada;

Received 3 July 2016; revised 13 November 2016; accepted 16 November 2016

Address for correspondence: Marie-Constance Lacasse, MD, FRCPC., Radiology Resident, Department of Radiology, University of Montreal and CRCHUM, Hôpital Saint-Luc, 1058 rue Saint-Denis, Montréal, Québec, Canada, H2X 3J4. E-mail: marie-constance.lacasse@mail.mcgill.ca

[Corrections added on 15 February 2017, after first online publication. The affiliations of authors S. Spahis and M. Chagnon were changed. The acknowlegement section was also updated.]

Introduction

Non-alcoholic fatty liver disease (NAFLD) is found in 34.2% of children with obesity (1) and is the leading cause of chronic liver disease in pediatrics (2). Obesity and chronic liver steatosis are associated with early-stage atherosclerotic changes that predict future cardiovascular risk (3). Carotid intima–media thickness (IMT) has been shown to be already increased in children with obesity, especially those affected with type 2 diabetes (4,5).

The management of children with obesity is multifaceted and challenging. The main strategy consists on the institution of a balanced diet, accompanied by changes in physical activity (6). Maintaining a healthy lifestyle is...
challenging to children with obesity. Pharmacological treatments are under-utilized for children and adults. While bariatric surgery is safe and effective for adolescents, it also is under-utilized (7). Laparoscopic adjustable gastric banding (LABG) for children with a BMI over 35 kg/m$^2$ (8) has proven to reduce hepatic steatosis (9), but is reserved only for very specific cases with severe medical complications secondary to obesity (10).

Omega-3 polyunsaturated fatty acids were found to act on multiple pathways implicated in the pathophysiology of hepatic steatosis. Their role in improving insulin resistance, decreasing dyslipidemia associated with hypertriglyceridemia, and acting both as an anti-inflammatory and anti-oxidative agent are potential mechanisms that may help prevent or at least lower liver steatosis in children with obesity (11–14) and ameliorate their lipid profile (15). Omega-3 supplementation has shown promising results in decreasing liver steatosis in animal studies (16–19), pilot clinical investigations in adults (20,21) and randomized trials in adults (22–25). The effect of omega-3 supplementation on carotid IMT has also been studied in adults with conflicting results (26–29), leading Balk et al. to conclude to insufficient data in a review article (30).

To quantitate liver steatosis in a pediatric population, noninvasive imaging-based methods are preferable to liver biopsy because of poor acceptance and risks of complications (31,32). Magnetic resonance (MR) may be used as a surrogate biomarker of fat content for short-term trials when serial biopsies are not practical (33). MR spectroscopy (MRS) is accepted as the noninvasive reference standard for fat quantification in children and can be used for longitudinal monitoring of fat fraction (34–36). MR imaging permits evaluation of the entire liver parenchyma. Although ultrasound (US) allows qualitative fat evaluation, it remains less studied than MR for liver quantitative fat grading (37–39). However, it is a good tool for evaluation of artery wall thickness. Furthermore, this modality would enable assessment of liver steatosis and carotid IMT within the same imaging session (40).

The primary aim of this study was to determine the effects of omega-3 supplementation on liver steatosis and carotid IMT in children with obesity. A secondary objective was to assess the diagnostic accuracy of US for grading liver steatosis using MRS as the reference standard.

**Materials and methods**

**Study design**

This is an ancillary imaging pilot study to a prospective, doubled-blinded, one-way crossover randomized clinical trial registered as NCT02201160 on www.clinicaltrials.gov, approved and reviewed by the Clinical Research Ethics Committee of the Centre Hospitalier Universitaire (CHU) Ste-Justine in Montréal, Canada. All subjects provided written informed consent.

**Participants**

Between March 2009 and July 2011, children with obesity were pre-screened by the Metabolic Unit of the Nutrition Department from two pediatric institutions (CHU Ste-Justine and Montreal Children’s Hospital).

**Eligibility criteria**

**Inclusion criteria**

Children with obesity and a body mass index (BMI) > 95th percentile were eligible to participate in this study if they were older than 8 years old (to allow MR without need for sedation), and showed hepatic steatosis on a baseline screening abdominal US. Contraceptive measures for female subjects of reproductive capacity were provided if required.

**Exclusion criteria**

Subjects were excluded if they had an identifiable secondary cause explaining their hepatic steatosis, had absolute contra-indications for MR or were taking any medication or supplementation that could interfere on the study results (anti-inflammatory drugs, medications for dyslipidemia and/or hypertension).

Eligible subjects who consented to the study were scheduled for an assessment by the participating pediatric hepatologist (F.A.).

**Randomization**

Children with obesity and liver steatosis were subsequently randomized. Investigators and study participants were blinded to the treatment allocation. Investigators were also blinded to imaging results until data analysis.

**Interventions**

Subjects were randomly assigned to either a daily dose 1.2 g of omega-3 or inactive sunflower oil (Nutrisanté Inc./Ponroy, Canada). The overall study lasted 9 months for each patient, divided in three distinct trimesters. During the first trimester, the subjects were randomly assigned either to omega-3 supplement or sunflower oil.
In the second trimester, the study was designed as a one-way crossover, with the subjects on omega-3 remaining on the same treatment, and the subjects on sunflower oil switching over to omega-3 supplementation. The last trimester was used as an observation period, with no treatments given to all groups.

Study visits

In total, four (4) clinical evaluations were scheduled: one at baseline (i.e. at the beginning of treatment), followed by visits at 3, 6 and 9 months after beginning the study. Each visit consisted in a half-day session to the Gastroenterology/Hepatology Unit, where the diverse inclusion and exclusion criteria were reviewed and the patient's nutritional and energetic status as well as anthropometric measurements was assessed. Subjects also underwent a complete physical examination, some biochemical testing, a carotid Doppler examination and a liver US and MR examination. Compliance was measured by pill count at every visit, review of the medication record and direct interview of the patients by the physician. All visits were similar.

Ultrasound fat grading

Semi-quantitative fat grading was performed by visual assessment using the scoring system adapted from Hamaguchi et al. (41). The scoring system was based on the presence or absence of liver–kidney contrast, US attenuation and vessel blurring. For each US study, a total steatosis score (from 0 to 6) was calculated as the unweighted sum of the three indices.

MR imaging fat quantification

All studies were acquired on a 1.5T clinical system (Avanto, Siemens Healthcare, Erlangen, Germany) with a body coil. Spoiled gradient-echo sequences with seven echoes were acquired during breath-holds. Sequence parameters were: flip angle, 20°; field of view, 350 mm (adapted to patient size); matrix, 256 × 166; section thickness, 10 mm; gap, 0 mm; receiver bandwidth, 780 Hz/pixel; voxel size, 2.5 mm × 2.5 mm × 10.0 mm; acceleration factor, none applied; number of averages, 1; repetition time (TR), 30 ms. The echo times (TE) were 2.3, 4.5, 6.8, 9.0, 11.3, 13.5 and 15.8 ms. Total acquisition time was typically 77 s for entire liver coverage.

Statistical analysis

Categorical variables were expressed as numbers and percentages. Continuous variables were expressed as
mean ± standard deviation (SD). Intra-individual comparisons between groups at baseline were analysed with the Student’s t-test or Chi-square. Comparisons between groups were performed with mixed model repeated-measure analysis of variance (ANOVA) with two factors, one factor ‘time’ at four levels (visit 1, 2, 3 and 4), one factor ‘group’ with two levels (24-week omega-3 group, 12-week omega-3 group). In case of interaction, the specific contrasts were used to study separately the evolution of each group and to compare groups at each visit. Fat grading accuracy of US was assessed by receiver operating characteristic (ROC) curves. Estimates of diagnostic performance (sensitivity, specificity) were assessed for MRS-determined fat fraction thresholds of ≥6.4%, ≥17.4% and ≥22.1% according to thresholds derived from Tang et al. (47) for inferred steatosis grades 0 vs. 1–2–3, 0–1 vs. 2–3 and 0–1–2 vs. 3, respectively. P values < 0.05 were considered significant. All statistical analyses were performed by a biostatistician (M.C.) with statistical software (SPSS for Windows, version 22.0; IBM, Chicago, Ill).

Results

Study population

Between March 2009 and July 2011, 22 children with obesity and hepatic steatosis met eligibility criteria and consented to participate in the study. Three subjects only attended the first baseline visit before dropping out, and were therefore not included in the statistical analysis. In the 19 subjects showing baseline hepatic steatosis, 10 were randomized to the 24-week omega-3 group, and 9 to the 12-week omega-3 group. Ten subjects (45.5%) completed the entire study, which included being present for all clinical assessments and performing all necessary imaging studies. Of these 10 subjects, five were in the 24-week omega-3 group, and five were in the 12-week omega-3 group.

The total study population included 16 (84.2%) males and 3 (15.8%) females. The mean age was 13.7 ± 3.0 years. The mean BMI was 31.2 ± 5.3 kg/m². Baseline characteristics were similar between the groups, except for height and waist circumference (Table 1). At baseline, liver fat content was higher in the steatosis group 24-week omega-3 group than in the 12-week group, whether assessed by MRS, MRI or US. Carotid IMT was similar between both groups. No adverse events were reported during the course of the study.

Effect of omega-3 and sunflower oil on liver fat content

The liver mean fat fraction was not significantly affected by omega-3 or sunflower oil supplementation (Figure 1). In the 24-week omega-3 group, the MRS-determined liver fat fraction decreased by 0.7% (22.4% at visit 1 to 21.7% at visit 3). In the 12-week omega-3 group, the liver fat fraction increased by 1.0% (15.4% at visit 1 to 16.4% at visit 2) during the sunflower oil period, and decreased by 2.1% (16.4% at visit 2 to 14.3% at visit 3) during omega-3 supplementation. None of the changes were significant as shown below.

MR spectroscopy and MR imaging

We did not observe an overall significant interaction between visit and group (F(3, 35.554) = 0.554, P = 0.649). Furthermore, we also did not observe a significant visit effect (F(3, 35.554) = 0.790, P = 0.508). Thus, liver fat fraction as measured by MRS and MRI was stable over the four visits in the two groups.

Ultrasound steatosis score

We did not observe an overall significant interaction between visit and group (F(3, 44.060) = 0.410, P = 0.747). Hence, the evolution of US steatosis scores between the two different regimens of omega-3 was not significantly different. We also did not observe a significant visit effect (F(3, 44.060) = 0.509, P = 0.678). Thus, liver fat fraction as measured by US steatosis score was stable over the four visits in the two groups.

Ultrasound fat grading accuracy

At baseline visit, the diagnostic performance estimates of semi-quantitative US for fat grading are provided in detail with 95% confidence intervals in Table 2. In summary, a ≥1.5 steatosis score threshold has a 0.964 area under the ROC curve, 85.7% sensitivity, 100.0% specificity, 100.0% positive predictive value (PPV) and 50.0% negative predictive value (NPV) for detecting MRS threshold ≥6.4% (which corresponds to inferred steatosis grade 0 vs. 1–2–3); a ≥2.5 steatosis score threshold has a 0.817 area under the ROC curve, 100.0% sensitivity, 55.6% specificity, 63.6% PPV and 100.0% NPV for detecting MRS threshold ≥6.4% (which corresponds to inferred steatosis grade 0 vs. 1–2–3); and a ≥2.5 steatosis score threshold has a 0.783 area under the ROC curve, 100.0% sensitivity, 50.0% specificity, 54.6% PPV and 100.0% NPV for detecting MRS threshold ≥22.1% (which corresponds to inferred steatosis grade 0–1–2 vs. 3) (Figure 2).

Effect of omega-3 on Ultrasound IMT

The baseline mean IMT was 0.60 ± 0.1 mm in both groups.
## Table 1 Baseline characteristics

| Characteristic                  | 24-week omega-3 (n = 10) | 12-week omega-3 (n = 9) | Total (n = 19) | P-value (24-week omega-3 vs. 12-week omega-3) |
|---------------------------------|---------------------------|-------------------------|----------------|---------------------------------------------|
| **Demographic**                 |                           |                         |                |                                             |
| Sex, n (%)                      |                           |                         |                |                                             |
| Male                            | 9 (90%)                   | 7 (77.8%)               | 16 (84.2%)     | 0.582                                       |
| Female                          | 1 (10%)                   | 2 (22.2%)               | 3 (15.8%)      |                                             |
| Age (years)                     | 14.5 ± 3.2                | 12.9 ± 2.6              | 13.7 ± 3.0     | 0.418                                       |
| Weight (kg)                     | 99.4 ± 29.1               | 74.4 ± 17.0             | 87.6 ± 26.8    | 0.036                                       |
| Height (m)                      | 1.7 ± 0.1                 | 1.6 ± 0.1               | 1.7 ± 0.2      | 0.023                                       |
| Body mass index (kg/m²)         | 32.6 ± 5.6                | 29.7 ± 4.9              | 31.2 ± 5.3     | 0.246                                       |
| Systolic blood pressure (mm Hg) | 122.6 ± 15.4              | 113.3 ± 15.3            | 118.4 ± 15.6   | 0.218                                       |
| Diastolic blood pressure (mm Hg)| 62.8 ± 8.5                | 56.6 ± 6.1              | 60.1 ± 8.0     | 0.092                                       |
| Heart rate (bpm)                | 79.6 ± 6.3                | 86.6 ± 15.5             | 82.7 ± 11.5    | 0.260                                       |
| Waist circumference (cm)        | 108.1 ± 16.6              | 92.8 ± 11.4             | 100.8 ± 16.1   | 0.031                                       |
| Hip circumference (cm)          | 113.7 ± 14.4              | 103.9 ± 10.3            | 109.1 ± 13.3   | 0.105                                       |
| **Biochemical**                 |                           |                         |                |                                             |
| Fasting plasma glucose (mmol/L) | 5.2 ± 0.4                 | 5.3 ± 0.4               | 5.3 ± 0.4      | 0.617                                       |
| Insulin (pmol/L)                | 187.9 ± 130.3             | 129.5 ± 61.0            | 158.7 ± 103.2  | 0.248                                       |
| Alanine aminotransferase (U/L)  | 52.8 ± 16.4               | 54 ± 65.7               | 53.4 ± 46.5    | 0.958                                       |
| Aspartate aminotransferase (U/L)| 34.2 ± 6.4                | 37.3 ± 34.8             | 35.8 ± 24.4    | 0.798                                       |
| Triglycerides (mmol/L)          | 1.5 ± 1.4                 | 1.5 ± 0.4               | 1.5 ± 1.0      | 0.935                                       |
| **Liver MR**                    |                           |                         |                |                                             |
| Mean MRS (%)                    | 21.9 ± 10.9               | 15.4 ± 12.5             | 18.6 ± 11.8    | 0.291                                       |
| Mean MRI-PDFF (%)               | 26.8 ± 12.4               | 21.3 ± 18.6             | 24.1 ± 15.5    | 0.503                                       |
| **Liver ultrasound**            |                           |                         |                |                                             |
| Liver-kidney contrast, n (%)    |                           |                         |                |                                             |
| 0 = liver hypoechoic relative to kidney | 0 (0%)                  | 1 (11.1%)               | 1 (5.3%)       | 0.730                                       |
| 1 = mild hyperechoic liver relative to kidney | 1 (10%)               | 2 (22.2%)               | 3 (15.8%)      |                                             |
| 2 = moderate hyperechoic liver relative to kidney | 2 (20%)               | 2 (22.2%)               | 4 (21.1%)      |                                             |
| 3 = marked hyperechoic liver relative to kidney | 7 (70%)               | 4 (44.4%)               | 11 (57.9%)     |                                             |
| Ultrasound deep attenuation, n (%)|                         |                         |                |                                             |
| 0 = no deep attenuation        | 3 (30%)                   | 5 (55.6%)               | 8 (42.1%)      | 0.141                                       |
| 1 = visible, blurred diaphragm  | 3 (30%)                   | 4 (44.4%)               | 7 (36.8%)      |                                             |
| 2 = undistinguishable diaphragm | 4 (40%)                   | 0 (0%)                  | 4 (21.1%)      |                                             |
| Vessel blurring, n (%)          |                           |                         |                |                                             |
| 0 = no vessel blurring         | 1 (10%)                   | 5 (55.6%)               | 6 (31.6%)      | 0.057                                       |

Continues
Carotid IMT showed a 0.05-mm decrease in the 24-week omega-3 group (Figure 3). The 12-week omega-3 group showed a 0.007-mm decrease during the sunflower oil period (between visits 1 and 2), and a 0.015-mm increase during omega-3 supplementation (between visits 2 and 3).

We did not observe significant interaction between visit and group \((F (3, 29.846) = 2.899, P = 0.051)\). Hence, the evolution of IMT between the two steatosis groups was not significantly different. However, we did observe a significant visit effect \((F (3, 29.846) = 5.868, P = 0.003)\), with carotid IMT significantly decreased between visit 4 as compared with visit 1 \((P = 0.005)\) and visit 2 \((P = 0.007)\). No significant group effect \((F (1, 15.889) = 1.592, P = 0.225)\) was found.

### Discussion

This prospective, double-blinded, one-way crossover randomized control trial compared the effect of treatment with 1.2 g daily of omega-3 versus sunflower oil on liver steatosis in children with obesity and baseline liver steatosis. Liver fat quantification was assessed by MRS as the reference standard, as well as by US and MRI. Carotid IMT was assessed by US.

In our study, omega-3 supplementation caused no significant effect on liver fat fraction as measured by MRS, MRI or US, and was not associated with a treatment duration effect [i.e. 24-week vs. 12-week supplementation]. Omega-3 supplementation was associated with a trend towards decrease in carotid IMT between visits \((P = 0.003)\), and this effect was stronger with longer treatment intervals. However, IMT changes were not significantly different between the omega-3 and sunflower oil groups. The trend towards carotid IMT reduction associated with omega-3 supplementation should be explored in larger cohorts.

Our results also showed excellent or good accuracy for US-based fat grading, using MRS as the reference standard for fat quantification and for inferring steatosis grade. The area under the ROC curve was 0.964 for detection of mild-to-severe steatosis \(\geq 6.4\%\) by MRS, 0.817 for detection of moderate to severe steatosis \(\geq 17.4\%\) by MRS) and 0.783 for detection of severe steatosis \(\geq 22.1\%\) by MRS). These preliminary results suggest that a semi-quantitative approach may have a diagnostic accuracy similar to that of quantitative US (area under the curve (AUC) = 0.98) for detection of steatosis \(\geq 6.0\%\) by MRI proton density fat fraction) (48).

Nearly all clinical studies that have previously assessed the effect of omega-3 on liver steatosis have been
performed on adult subjects (49). While these studies differ in study design (pilot clinical studies, randomised controlled trials [RCT] and systematic review), dosage (from 0.83 g daily (24) up to 9 g daily (50)), duration (from 8 weeks (23,50) to 12 months (20,21,24)) and technique for assessing liver steatosis (mostly US and MRI), most have been conducted on a small number of patients (at most 134 patients (51)) and have reported a beneficial effect of omega-3 supplementation. Available RCTs demonstrate some liver fatty regression in the majority of the patients after assessment with US (22,24,51) or MRS (23). A RCT study performed on a pediatric population (25) reported less odds of having severe hepatic steatosis after 6 months of omega-3 supplementation, with persisting beneficial effects up to 24 months (52). However, a more recent RCT in children showed no effect of omega-3 supplementation on liver steatosis on US (53). The result of our study is hence concordant with this RCT, which also studied a similar patient population.

Most available investigations studying the effect of omega-3 supplementation on carotid IMT are observational studies targeting Northern European populations, communities in small fishing villages in Japan and
Native American populations (26,54,55), thought to have a higher baseline dietary consumption of marine oils.

Table 2

| Inferred steatosis grade | MRS thresholds (%) | US steatosis score thresholds | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------------------------|--------------------|-----------------------------|----------------|----------------|---------|---------|
| 0 vs. 1 – 2             | ≥ 0.964 [0.864; 1.000] | ≥ 0.56 [0.56; 1.000] | 85.7 [56.2; 97.5] | 100.0 [100.0; 100.0] | 100.0 [100.0; 100.0] |
| 0 vs. 1 – 2             | ≥ 0.964 [0.864; 1.000] | ≥ 0.56 [0.56; 1.000] | 85.7 [56.2; 97.5] | 100.0 [100.0; 100.0] | 100.0 [100.0; 100.0] |
| 0 vs. 1 – 2             | ≥ 0.964 [0.864; 1.000] | ≥ 0.56 [0.56; 1.000] | 85.7 [56.2; 97.5] | 100.0 [100.0; 100.0] | 100.0 [100.0; 100.0] |
| 0 vs. 1 – 2             | ≥ 0.964 [0.864; 1.000] | ≥ 0.56 [0.56; 1.000] | 85.7 [56.2; 97.5] | 100.0 [100.0; 100.0] | 100.0 [100.0; 100.0] |
| 0 vs. 1 – 2             | ≥ 0.964 [0.864; 1.000] | ≥ 0.56 [0.56; 1.000] | 85.7 [56.2; 97.5] | 100.0 [100.0; 100.0] | 100.0 [100.0; 100.0] |

Note: Numbers in brackets are 95% confidence intervals. AUC, area under the receiver operating characteristic curve; MRS, magnetic resonance spectroscopy; NPV, negative predictive value; PPV, positive predictive value.

Figure 2 Receiver operating characteristic curve analysis of ultrasound for classification of liver fat grades compared to the magnetic resonance spectroscopy as the reference standard at 6.4% (inferred steatosis grades 0 vs. ≥ 1), 17.4% (inferred steatosis grades ≤ 1 vs. ≥ 2) and 22.1% fat fraction thresholds (inferred steatosis grades ≤ 2 vs. 3).

Figure 3 Variations through groups and visits of mean carotid intima–media thickness (IMT) as measured by ultrasound (mm). Blue = 24-week omega-3 group. Green = 12-week omega-3 group.

Native American populations (26,54,55), thought to have a higher baseline dietary consumption of marine oils. Most cross-sectional studies showed decreased carotid
IMT and lower plaque incidence (26,28,56). Results from RCTs previously showed no effect of omega-3 supplementation on carotid IMT (27,29). However, a recent study found a reduced progression of carotid IMT following omega-3 treatment (57). Only one RCT was performed on a pediatric population (55), and although showing promising preliminary results, no long-term benefits of omega-3 supplementation were found (58). Hence, the only systematic review available (30) concluded that because of scarcity of valid RCT, it was impossible to draw conclusion as to the effect of omega-3 on carotid IMT.

In our study, MRS was used as a surrogate reference standard for the estimation of liver fat fraction. While histological assessment remains the definitive reference standard for the measurement of liver fat fraction, it would have been unacceptable to submit asymptomatic children to repeated liver biopsies, exposing them to a painful experience and to the non-negligible risks of complications. Furthermore, as stated by Sanyal et al. (33), the spectrum of NAFLD is less well defined in children, and the histologic endpoints are more variable. As suggested, non-invasive imaging studies (MRI and MRS) might be acceptable in a pediatric population in order to monitor variations in steatosis in short-term clinical trials. While the thresholds used for dichotomization of steatosis severity were originally based on MRI-PDFF technique, they were transposed to MRS for this study because of the strong correlation between these MR-based techniques (47,59).

The main limitation of our study is the small number of subjects included in the statistical analysis, as only 22 subjects were recruited, and 10 subjects (45.5%) completed all four clinical visits and various imaging studies. Challenges in patient enrollment and significant drop-out rate may be explained by the length of the study. Also, the subjects were required to miss 4 days of school for this clinical study, which limits acceptance, both from parents and study participants. The small number of subjects included in this study might have been insufficient to detect a small benefit of Omega-3 supplementation over sunflower oil (type 2 error).

**Conclusion**

In conclusion, omega-3 supplementation had no significant effect on liver fat content but led to a decrease in carotid IMT in children with obesity and hepatic steatosis. Future and larger clinical trials in children with obesity are required to confirm the long-term effect of omega-3 supplementation on carotid IMT.

**Conflict of Interest Statement**

The authors declare no conflict of interest.

**Authors’ Contribution and Acknowledgements**

Authors listed on the title page have participated in the conception and design of this work or the analysis and interpretation of the data, as well as the writing of the manuscript, and take public responsibility for it. We believe the manuscript represents valid work. We have reviewed the final version, and approve it for publication. Neither this manuscript nor one with substantially similar content under our authorship has been published or is being considered for publication elsewhere.

A.T. is supported by a clinical research scholarship from the Fonds de recherche du Québec en Santé (FRQ-S) and Fondation de l’association des radiologistes du Québec (#26993).

The present work was supported by the JA DeSève Research Chair in Nutrition (EL), NSERC (EL), Diabète Québec (EL), FRQS doctoral Scholarship Award (SS), and NutriSanté Inc/Ponroy (Canada) (financial support and gift of n-3 PUFA capsules). The authors thank the patients who participated in the trial and are grateful to Dr Nadjma Ahmad for providing patients from the Montreal Children’s Hospital.

**References**

1. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. *PLoS One* 2015; 10: e0140908.

2. Hecht L, Weiss R. Nonalcoholic fatty liver disease and type 2 diabetes in obese children. *Curr Diab Rep* 2014; 14: 448.

3. Jordan J, Nilsson PM, Kotsis V et al. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and early vascular ageing. *J Hypertens* 2015; 33: 425–434.

4. Stabouli S, Kotsis V, Papamichael C, Constantopoulos A, Zakopoulos N. Adolescent obesity is associated with high ambulatory blood pressure and increased carotid intimal–medial thickness. *J Pediatr* 2005; 147: 651–656.

5. Naylor LH, Green DJ, Jones TW et al. Endothelial function and carotid intima-medial thickness in adolescents with type 2 diabetes mellitus. *J Pediatr* 2011; 159: 971–974.

6. Spear BA, Barlow SE, Ervin C et al. Recommendations for treatment of child and adolescent overweight and obesity. *Pediatrics* 2007; 120: S254–S288.

7. Inge TH, Zeller MH, Jenkins TM et al. Perioperative outcomes of adolescents undergoing bariatric surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. *JAMA Pediatr* 2014; 168: 47–53.
8. O’Brien PE, Sawyer SM, Laurie C et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. JAMA 2010; 303: 519–526.

9. Loy JJ, Youn HA, Schwack B, Kurian M, Ren Fielding C, Fielding GA. Improvement in nonalcoholic fatty liver disease and metabolic syndrome in adolescents undergoing bariatric surgery. Surg Obes Relat Dis 2015; 11: 442–449.

10. Nobili V, Vajro P, Dezsofi A et al. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2015; 60: 550–561.

11. Harris WS, Dujovne CA, Zucker M, Johnson B. Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial. Ann Intern Med 1988; 109: 465–470.

12. Kremer JM, Lawrence DA, Jubiz W et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990; 33: 810–820.

13. Furukawa K, Tashiro T, Yamamori H et al. Effects of soybean oil emulsion and eicosapentaenoic acid on stress response and immune function after a severely stressful operation. Ann Surg 1999; 229: 255–261.

14. Salmeron J, Hu FB, Manson JE et al. Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001; 73: 1019–1026.

15. Spahis S, Alvarez F, Dubois J, Ahmed N, Peretti N, Levy E. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. Prostaglandins Leukot Essent Fatty Acids 2015; 99: 25–34.

16. Sekiya M, Yahagi N, Matsuoka T et al. Polynsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529–1539.

17. Gonzalez-Periz A, Horrillo R, Ferre N et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23: 1946–1957.

18. Jung UJ, Millman PN, Tall AR, Deckelbaum RJ. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice. Biochim Biophys Acta 2011; 1811: 491–497.

19. Valenzuela R, Espinosa A, Gonzales-Manan D et al. N-3 long-chain polynsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One 2012; 7: e46400.

20. Capani M, Calella F, Ibagni MR et al. Prolonged n-3 polynsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143–1151.

21. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413–418.

22. Spadarolo M, Magliocco O, Spampinato D et al. Effects of n-3 polynsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40: 199–194.

23. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842–3848.

24. Sofi F, Giangrandi I, Cesari F et al. Effects of a 1-year dietary intervention with n-3 polynsaturated fatty acid–enriched olive oil on non-alcoholic fatty liver disease in patients: a preliminary study. Int J Food Sci Nutr 2010; 61: 792–802.

25. Nobili V, Bedogni G, Alisi A et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled trial. Arch Dis Child 2011; 96: 350–353.

26. Yamada T, Strong JP, Ishii T et al. Atherosclerosis and omega-3 fatty acids in the populations of a fishing village and a farming village in Japan. Atherosclerosis 2000; 153: 469–481.

27. Angerer P, Kothny W, Stork S, von Schacky C. Effects of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res 2002; 54: 183–190.

28. Djuose L, Folsom AR, Province MA, Hunt SC, Ellison RC. Dietary linolenic acid and carotid atherosclerosis: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr 2003; 77: 819–825.

29. Bemelmans WJ, Lefrandt JD, Feskens EJ et al. Increased alphalinolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. Eur J Clin Nutr 2004; 58: 1083–1089.

30. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19–30.

31. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495–500.

32. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017–1044.

33. Sanyal AJ, Brunt EM, Kleiner DE et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344–353.

34. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297–2307.

35. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011; 34: 729–749.

36. Schwimmer JB, Middleton MS, Behling C et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 2015; 61: 1887–1895.

37. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver- Kidney contrast. Tohoku J Exp Med 1983; 139: 43–50.

38. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 746–750.

39. Saadeh S. Nonalcoholic fatty liver disease and obesity. Nutr Clin Pract 2007; 22: 1–10.

40. O’Leary DH, Polak JF. Intima–media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90: 18L–21L.

41. Hamaguchi M, Kojima T, Itoh Y et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708–2715.

42. Yokoo T, Bydder M, Hamilton G et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle
multiecho gradient-recalled-echo MR imaging at 1.5 T. *Radiology* 2009; 251: 67–76.

43. Hamilton G, Yokoo T, Bydder M et al. In vivo characterization of the liver fat (1)H MR spectrum. *NMR Biomed* 2011; 24: 784–790.

44. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. *J Magn Reson* 1997; 129: 35–43.

45. Naressi A, Couturier C, Devos JM et al. Java-based graphical user interface for the MRUI quantitation package. *MAGMA* 2001; 12: 141–152.

46. Touboul PJ, Hennerici MG, Meairs S et al. Mannheim carotid intima–media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. *Cerebrovasc Dis* 2007; 23: 75–80.

47. Tang A, Tan J, Sun M et al. Nonalcoholic fatty liver disease; MR imaging of liver proton density fat fraction to assess hepatic steatosis. *Radiology* 2013; 267: 422–431.

48. Lin SC, Heba E, Wolfson T et al. Noninvasive diagnosis of non-alcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. *Clin Gastroenterol Hepatol* 2015; 13: 1437–1435.

49. Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol* 2012; 56: 944–951.

50. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Effects of N-3 fatty acids on hepatic triglyceride content in humans. *J Invest Med* 2008; 56: 780–785.

51. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. *World J Gastroenterol* 2008; 14: 6395–6400.

52. Nobili V, Alisi A, Della Corte C et al. Docosahexaenoic acid for the treatment of fatty liver. Randomised controlled trial in children. *Nutr Metab Cardiovasc Dis* 2013; 23: 1066–1070.

53. Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A et al. Omega-3 fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. *J Pediatr* 2015; 166: 1358–1563.

54. Ebbesson SO, Roman MJ, Devereux RB et al. Consumption of omega-3 fatty acids is not associated with a reduction in carotid atherosclerosis: the Genetics of Coronary Artery Disease in Alaska Natives study. *Atherosclerosis* 2008; 199: 346–353.

55. Skilton MR, Mikkila V, Wurtz P et al. Fetal growth, omega-3 (n-3) fatty acids, and progression of subclinical atherosclerosis: preventing fetal origins of disease? The Cardiovascular Risk in Young Finns Study. *Am J Clin Nutr* 2013; 97: 58–65.

56. Sala-Vila A, Cofan M, Perez-Heras A et al. Fatty acids in serum phospholipids and carotid intima–media thickness in Spanish subjects with primary dyslipidemia. *Am J Clin Nutr* 2010; 92: 186–193.

57. Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima–media thickness progression. *Atherosclerosis* 2016; 246: 13–20.

58. Ayer JG, Harmer JA, Xuan W et al. Dietary supplementation with n-3 polyunsaturated fatty acids in early childhood: effects on blood pressure and arterial structure and function at age 8 y. *Am J Clin Nutr* 2009; 90: 438–446.

59. Yokoo T, Shiehmorteza M, Hamilton G et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. *Radiology* 2011; 258: 749–759.